Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
X. Li (Tianjin, China), Z. Lv (Tianjin, China), K. Huang (Tianjin, China), W. Gan (Tianjin, China), S. Gao (Tianjin, China), B. Yang (Tianjin, China), K. Helian (Tianjin, China), H. Zhou (Tianjin, China). Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model. 5377

Member's Comments

No comment yet.

Related content which might interest you: Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis Year: 2010 Time course of bleomycin-induced pulmonary fibrosis and the antifibrotic effect of losartan Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease Year: 2007 Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats Source: Eur Respir J 2006; 28: Suppl. 50, 827s Year: 2006 Therapeutic effect of combination of salvia and ligustrazine on bleomycin-induced pulmonary fibrosis Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 A translational value of pulmonary function tests in a mouse model of bleomycin-induced pulmonary fibrosis: effects of approved therapies Nintedanib and Pirfenidone Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 PBI-compound, a novel first-in-class anti-fibrotic compound, reduces lung fibrosis in the bleomycin-induced lung fibrosis model: A comparative study with pirfenidone Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Antioxidant and anti-inflammation effect of GHK-Cu in bleomycin-induced pulmonary fibrosis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis:  mechanistic insights and prognostic markers Year: 2018 Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 The effect of pravastatin on bleomycin-induced lung injury and fibrosis in mouse Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Effect of curcumin on inflammation in experimental pulmonary fibrosis Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Roles of α1-acid glycoprotein in therapeutic effects of imatinib in bleomycin-induced pulmonary fibrosis: benefits of macrolides Source: Annual Congress 2007 - Recent advances in the understanding of lung injury and repair Year: 2007 HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Effect of nintedanib on silica-induced lung inflammation and fibrosis in mice Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside Year: 2012 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015